) has been revised to $13.77 / share. This is an increase of 12.50% from the prior estimate of $12.24 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...
Patient-Centric Data Capture Fuels Growth of Target RWE Longitudinal, Real-World Dermatology Studies
DURHAM, N.C., March 7, 2025 /PRNewswire/ -- Real-world evidence (RWE) leader, Target RWE, announced updates from its longitudinal dermatology study of more than 7,000 enrolled patients with two poster ...
DURHAM, N.C., Feb. 28, 2023 /PRNewswire/ -- Real world evidence (RWE) leader, Target RWE, today shared new updates and insights from its longitudinal dermatology community of more than 4,000 patients, ...
DURHAM, N.C., Feb. 27, 2019 /PRNewswire/ -- TARGET PharmaSolutions, Inc., a real-world clinical data solutions company, is pleased to announce that Novartis Pharma AG is the first industry partner to ...
Dr. Muneeb Shah is taking his skin care brand, Remedy, to retail. The brand, which debuted in 2024, is launching its first retail partnership with Target Corp. on Dec. 28 in nearly 2,000 doors on ...
DURHAM, N.C., March 8, 2024 /PRNewswire/ -- New patient-reported outcomes data presented at AAD 2024 from Target RWE's TARGET-DERM AA registry confirms the high unmet need and significant disease ...
Target PharmaSolutions has named Novartis as its first TARGET-DERM registry industry partner. Target PharmaSolutions has named Novartis as its first industry partner to provide multi-year support to ...
The average one-year price target for Journey Medical (NasdaqCM:DERM) has been revised to $13.77 / share. This is an increase of 12.50% from the prior estimate of $12.24 dated November 7, 2025. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results